Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasia
The Department of Leukemia has established the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasia (HAP-CRC-MPN) as a distinct operational unit within the Leukemia Department and Leukemia Outpatient Center. The goal of this clinical research center is to develop a comprehensive approach to understanding the biology of myeloproliferative neoplasms through translational research, leading to new and effective therapies for myeloproliferative disorders.
Under the guidance of Dr. Srdan Verstovsek, Chief of the Section of Myeloproliferative Neoplasms, MD Anderson has become the largest center in the world for MPN patient referral and research. We see annually more than 250 new patients with MPN, far more than any other clinical center in the world, and are engaged continuously in clinical research (conduct of clinical studies) to try to find effective therapies. Nothing of similar proportion exists anywhere in the world.
Components of the HAP-CRC-MPN include:
- Clinical trials with novel agents developed specifically for patients with MPN
- Centralized tissue bank and database for collection and annotation of patient samples
- Education of physicians, patients and their families about the latest in research and treatment of MPNs
MD Anderson Resources
MPN Focus is a periodic newsletter published by the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasia to provide members of the MPN community with information on current research and treatments.